Results 61 to 70 of about 2,146 (159)

Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis

Journal of Health Economics and Outcomes Research
# Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder with C5 inhibitors (C5i), eculizumab and ravulizumab, being part of current treatment options.
Srinivas K Tantravahi, Dominick Latremouille-Viau, Raj Desai, Soyon Lee, Jincy Paulose, Anumaxine Geevarghese, Annie Guérin, Shravanthi Seshasayee, Mohin Chanpura, Glorian Yen   +9 more
doaj   +1 more source

Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies

Journal of Comparative Effectiveness Research
This summary gives an overview of three published articles that report the results of research studies of ravulizumab, an approved treatment for people with atypical hemolytic uremic syndrome (often shortened to aHUS).
Michal Nowicki, Nikoleta Printza
doaj   +1 more source

Ravulizumab

Reactions Weekly, 2022
openaire   +2 more sources

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network

Frontiers in Immunology
ObjectiveTo integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors ...
Luqiong Wang, Jiaojiao Chen, Huixiang Li, Lin Wang, Feiyu Liu, Xiaoli Jiang   +5 more
doaj   +1 more source

Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of a ...
Florencia Aguirre, Renata Andrade
doaj   +1 more source

Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland

eJHaem
Introduction Ravulizumab replaced eculizumab as the preferred complement inhibitor for Paroxysmal Nocturnal Haemoglobinuria (PNH) in Denmark and Finland after 2020. Data on real‐world disease activity after switching are limited.
Anders Rønneholt‐Frederiksen, Dennis Lund Hansen, Vuokko Nummi, Jesper Stentoft, Ulrik M. Overgaard, Rie Sander Bech, Anna‐Elina Lehtinen, Andreas Glenthøj, Henrik Frederiksen   +8 more
doaj   +1 more source

Ravulizumab as an alternative for gemcitabine related trombotic microangiopathy: A case report

Nefrología (English Edition)
Thrombotic microangiopathy (TMA) is characterized by endotelial damage, microangiopathic hemolytic anemia, thrombocytopenia and organ damage, particularly renal. In Oncology, TMA can be secondary to the cancer itself or related to oncological treatments.
Cristina Riaza Ortiz, Marta Calvo Arévalo, Marta Álvarez Nadal, Antonio Casado, Ana I. Sánchez-Fructuoso, Clara García-Carro   +5 more
doaj   +1 more source

Ravulizumab for relapse prevention in AQP4-IgG–positive neuromyelitis optica spectrum disorder: a 2-year follow-up case report

Frontiers in Medicine
BackgroundNeuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system, distinct from multiple sclerosis, characterized by severe inflammatory attacks targeting the optic nerves, spinal cord, and brainstem ...
Nabil Akkawi, Elkhansa Hassabo Mohamed, Ahmed Shatila   +2 more
doaj   +1 more source

Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial

Thrombosis Journal
Background Atypical hemolytic uremic syndrome (aHUS) is a rare disease with poor outcomes when untreated, in which ravulizumab or eculizumab are the standard of care where available.
Masanori Matsumoto, Akihiko Shimono, Jun Yokosawa, Keiichiro Hirose, Edward Wang, Shoichi Maruyama   +5 more
doaj   +1 more source

Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania

Brain Sciences
Background and Objectives: Ravulizumab, a long-acting C5 complement inhibitor, was approved in the US and Europe in 2022 as an add-on therapy for the standard treatment of AChR-positive generalized MG (gMG).
Crisanda Vîlciu, Oana Antonia Mihalache, Bogdan Marius Istrate, Mihaela Aftinia Marian, Mirela Ramona Drăghici, Diana Mihaela Petrescu, Adriana Octaviana Dulămea, Daniela Cristina Anghel   +7 more
doaj   +1 more source